Full Service Brochure - Antibody Discovery, Production, and Optimization

Biointron's latest webinar features Shun Zhou, Ph.D, the R&D Director at Cyagen: “Accelerating Antibody Discovery with Fully Human Antibody Mouse HUGO-Ab™ and Single B Cell Screening Technology AbDrop™”

This topic explores the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with microfluidic technology-enhanced single B cell screening, this approach allows for the high-throughput and efficient discovery of antibody drug molecules.

This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September).
https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html

This quarter saw an increase in research trends in higher drug–antibody ratios for antibody-drug conjugates (ADCs), with promising approaches to address the problem of high hydrophobicity. Positive results in various clinical trials for anti-TIGIT therapies have also excited the field, with safety and pharmacovigilance at the center after numerous failures. Here, we give an example of a promising monoclonal antibody in development.

To learn more, download the trends report here: https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html